Sarcopenia Drug Trials Face High Regulatory Bar With No Approved Endpoints Yet
A 2024 FDA workshop exposed deep gaps in sarcopenia diagnostics and trial design, with major regulatory hurdles blocking drug approval.
Summary
A December 2024 workshop convened academics, industry, and FDA officials to address why sarcopenia—despite 23,000+ publications—still lacks approved diagnostics, consensus definitions, or approved therapies. Key topics included the D3-creatine dilution method as a promising muscle mass tool, variability in CT-based measurements, and validated physical performance endpoints like the SPPB and gait speed. Novel therapies such as enobosarm, anamorelin, ponsegromab, and 20-hydroxyecdysone were reviewed. Regulators signaled that clinically meaningful outcomes—physical function, morbidity, or mortality—must be demonstrated, not just muscle mass changes. This high bar may make sarcopenia drug development economically viable only for therapies that significantly impact hard clinical outcomes.
Detailed Summary
Despite over three decades of research and more than 23,000 scientific publications, sarcopenia—the age-related loss of skeletal muscle mass and function—remains without a universally accepted definition, standardized diagnostic criteria, or a single FDA-approved therapy. This reality was the central tension explored at the December 2024 Regulatory and Trial Update Workshop hosted by the Society on Cachexia and Wasting Disorders (SCWD) in Washington, D.C., which brought together researchers, industry representatives, and FDA officials.
The workshop opened with a historical overview tracing the term 'sarcopenia' back to Irwin Rosenberg's 1988 proposal, and highlighted how evolving definitions—over 15 published to date—have moved away from muscle mass and toward functional measures like grip strength and gait speed. The original Baumgartner formula using DEXA-measured appendicular skeletal muscle mass indexed to height squared is now viewed as unreliable, with longitudinal data showing that strength declines faster than mass with aging, a distinction captured by the term 'dynapenia.' Meta-analyses reveal prevalence estimates ranging from 0–22% depending on the diagnostic tool used, underscoring the urgent need for standardization.
A major diagnostic innovation discussed was the D3-creatine (D3Cr) dilution technique, championed by Prof. William Evans. The method involves ingesting a small dose of deuterium-labeled creatine, which equilibrates across all skeletal and cardiac muscle, is converted to creatinine, and is then excreted in urine. A single urine sample analyzed by HPLC can yield total muscle mass estimates. Data from over 1,300 men aged 80+ in the MrOS cohort showed that DEXA-derived appendicular lean mass had no relationship with outcomes, while D3Cr muscle mass co-segregated with strength, physical performance, and disability. A study of 11,000 women conducted remotely demonstrated scalability. However, critics noted that D3Cr measures creatine dilution space—not muscle mass per se—and that validated prediction models across diverse populations are still lacking.
On trial endpoints, the workshop reviewed the Short Physical Performance Battery (SPPB), habitual gait speed, stair-climb tests, and the 6-minute walk test as clinically validated functional measures. Novel therapeutics reviewed included enobosarm (a selective androgen receptor modulator), anamorelin (a ghrelin receptor agonist), ponsegromab (anti-GDF-15), 20-hydroxyecdysone, and strategies targeting myostatin-activin signaling and Akt pathway activation. CT-based lumbar skeletal muscle index was discussed in detail, with emphasis on significant variability arising from instrument settings, imaging protocols, and reader interpretation.
The regulatory outlook was sobering. FDA representatives indicated that clinically meaningful changes in patient-reported outcomes, physical function, or morbidity/mortality must be demonstrated for drug approval. If mortality is not a primary endpoint, comprehensive safety data equivalent to that required for type 2 diabetes drugs—given the vast aging population potentially eligible—would be mandatory. Workshop participants warned this could make sarcopenia drug programs economically unfeasible unless therapies show clear impact on hard outcomes. A second FDA meeting on approving a diagnostic method for muscle mass measurement was noted as forthcoming, which would represent meaningful regulatory progress.
Key Findings
- Over 15 definitions of sarcopenia exist; none currently uses muscle mass alone as the diagnostic criterion.
- D3-creatine dilution outperformed DEXA appendicular lean mass in predicting disability in 1,300+ men aged 80+.
- FDA requires clinically meaningful functional or morbidity/mortality endpoints—muscle mass alone is insufficient for drug approval.
- Safety standards for sarcopenia drugs may mirror those for type 2 diabetes, potentially requiring massive, costly trials.
- Novel therapies including enobosarm, anamorelin, ponsegromab, and myostatin inhibitors are under active investigation.
Methodology
This is a meeting report summarizing the proceedings of the December 6, 2024 SCWD Regulatory and Trial Update Workshop in Washington, D.C. It synthesizes expert presentations and panel discussions from academics, industry, and FDA representatives rather than reporting original experimental data.
Study Limitations
As a meeting report, this article presents expert opinions and workshop discussions rather than new clinical trial data, limiting the strength of its conclusions. The D3-creatine dilution method, while promising, lacks validated predictive models across diverse age groups, sexes, and ethnicities. No consensus was reached at the workshop on a unified sarcopenia definition or regulatory pathway, reflecting the ongoing fragmentation of the field.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.